10-KPeriod: FY2023

DEXCOM INC Annual Report, Year Ended Dec 31, 2023

Filed February 8, 2024For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported strong revenue growth of 24% year-over-year, reaching $3.62 billion for the fiscal year ended December 31, 2023. This growth was primarily driven by increased sales volumes of their disposable continuous glucose monitoring (CGM) sensors, reflecting continued expansion of their global customer base. The company achieved significant improvements in profitability, with operating income up 53% and net income up 59% compared to the previous year. Dexcom's latest generation products, the G6 and G7 CGM systems, continue to drive adoption. The G7, launched in late 2022, offers key improvements such as a smaller profile, faster warm-up time, and enhanced features, further solidifying Dexcom's position in the diabetes management market. The company also noted ongoing progress in expanding its manufacturing capabilities and is actively pursuing strategic partnerships to broaden market access and enhance product offerings. Despite facing ongoing patent litigation with Abbott and various market risks, Dexcom's financial performance and strategic initiatives indicate a strong outlook for continued growth in the diabetes technology sector.

Financial Highlights

52 data points
Beta

Revenue

$3.62B

63.2% Gross Margin

Net Income

$541.50M

14.9% Net Margin

EPS (Diluted)

$1.30

Total Assets

$6.26B

Cash & Equivalents

$566.30M

Free Cash Flow

$511.90M

Financial Statements
Beta
Revenue$3.62B
Cost of Revenue$1.33B
Gross Profit$2.29B
R&D Expenses$505.80M
SG&A Expenses$1.19B
Operating Expenses$1.69B
Operating Income$597.70M
Interest Expense$16.40M
Net Income$541.50M
EPS (Basic)$1.40
EPS (Diluted)$1.30
Shares Outstanding (Basic)386.00M
Shares Outstanding (Diluted)425.50M

Key Highlights

  • 1Revenue grew 24% year-over-year to $3.62 billion.
  • 2Net income increased by 59% to $541.5 million.
  • 3Gross profit margin was 63.2%, with cost of sales increasing primarily due to higher sales volume.
  • 4Research and development expenses increased by 4%, reflecting continued investment in product innovation.
  • 5Selling, general, and administrative expenses rose 18%, largely due to higher compensation costs and marketing efforts for global product launches.
  • 6The company ended the year with $2.72 billion in cash, cash equivalents, and short-term marketable securities.
  • 7Dexcom is engaged in ongoing patent litigation with Abbott Diabetes Care.

Frequently Asked Questions

Dexcom's primary products are continuous glucose monitoring (CGM) systems, which include sensors, transmitters, and receivers (or compatible mobile devices). These systems track glucose levels in real-time, sending readings every five minutes to a display device. They offer features like customizable alerts, data sharing with caregivers, and integration with other diabetes management technologies, aiming to replace traditional fingerstick blood glucose testing for better diabetes management.

Dexcom's revenue growth is primarily driven by increased sales volume of its disposable CGM sensors. This growth is fueled by the expanding global customer base, the adoption of its latest generation products (G6 and G7), and efforts to broaden coverage and reimbursement from third-party payors and government programs.

Dexcom operates in a highly competitive market with key competitors including Abbott Laboratories and Medtronic. Competition centers on product performance, ease of use, cost, reimbursement, brand awareness, and technological innovation. Dexcom also faces competition from companies developing integrated insulin delivery systems and potentially from new entrants in the digital health and wellness space.

Dexcom plans to continue developing future generations of CGM technologies focused on improved performance and convenience, aiming to enable intelligent insulin administration. They are also exploring partnerships for automated insulin delivery systems and expanding their product offerings to include Type 2 diabetes patients not using insulin, pre-diabetes, and hospital settings. Future plans also include applying their technological expertise to products beyond glucose monitoring.